Vicore Pharma Holding AB
NASDAQ:VCREMedical - Pharmaceuticals
-$0.24 today
- Market cap
- $279.65M
- Beta
- 0.15
Volume 0.00M
Average 0.26M
VCRE Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Vicore Pharma Holding ABNASDAQ: VCRE
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization remains negative
Q2 FY2026 depreciation & amortization was SEK 15.48M, compared with SEK 0 a year earlier. Trailing-twelve-month depreciation & amortization was SEK 15.54M.
Context
- Depreciation & amortization amounted to 0.0% of revenue in FY2025, down 2.1 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near SEK 15.48M or moves back toward the trailing-twelve-month quarterly average of SEK 3.89M.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
SEK · from the income statement
- Latest · FY2025
- 0 SEK
- Year-over-year change
- -100.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 2.24M | -34.5% |
| FY2023 | 2023-12-31 | 3.42M | -5.2% |
| FY2022 | 2022-12-31 | 3.61M | +872.7% |
| FY2021 | 2021-12-31 | 371.33K | — |
Depreciation & Amortization vs competitors
How VCRE compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +27894.0% is the highest of 2, against a peer median of -9.0%.
- Depreciation & amortization amounts to 1168.5% of revenue for VCRE, versus a peer median of 0.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 15.54M SEK | +27894.0% | — | 1168.5% |
| LTM Jun 2026 | $1.69M USD | -9.0% | -25.2% | 0.4% | |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding VCRE) | — | -9.0% | -25.2% | 0.4% | |
Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 109.35M | 3.82M |
| Cost of Revenue | 3.58M | 0 | 0 | 0 | 0 |
| Gross Profit | (3.58M) | 0 | 0 | 109.35M | 3.82M |
| Gross Margin | — | — | — | 100.0% | 100.0% |
| Research & Development | 30.05M | 249.97M | 276.29M | 249.26M | 390.35M |
| Selling, General & Admin | 2.39M | 37.53M | 44.6M | 50.44M | 67.91M |
| Operating Expenses | 32.59M | 290.73M | 321.51M | 299.71M | 458.26M |
| Depreciation & Amortization | 371.33K | 3.61M | 3.42M | 2.24M | 0 |
| EBITDA | (32.07M) | (285.19M) | (307.9M) | (166.64M) | (477.41M) |
| EBITDA Margin | — | — | — | -152.4% | -12507.6% |
| Operating Income | (32.59M) | (290.73M) | (321.51M) | (190.36M) | (454.45M) |
| Operating Margin | — | — | — | -174.1% | -11905.8% |
| Interest Income | 70.2K | 913K | 10.54M | 21.08M | 23.89M |
| Interest Expense | 0 | 8K | 2K | 8K | 60K |
| Other Income / Expenses | (211.92K) | 1.92M | 10.18M | 21.47M | (23.03M) |
| Income Before Tax | (32.8M) | (288.81M) | (311.33M) | (168.89M) | (477.47M) |
| Pre-Tax Margin | — | — | — | -154.5% | -12509.1% |
| Income Tax Expense | (252.7K) | (384K) | (384K) | (256K) | 0 |
| Net Income | (294.97M) | (288.42M) | (310.94M) | (168.63M) | (477.47M) |
| Net Margin | — | — | — | -154.2% | -12509.1% |
| EPS (Basic) | (0.47) | (38.82) | (31.80) | (12.30) | (19.90) |
| EPS (Diluted) | (0.47) | (38.82) | (31.80) | (12.30) | (19.90) |
| Weighted Avg Shares | 69.68M | 7.42M | 9.66M | 13.68M | 23.99M |
| Weighted Avg Shares (Diluted) | 69.68M | 7.42M | 9.66M | 13.68M | 23.99M |
Vicore Pharma Holding AB
NASDAQ:VCRE
Intrinsic Alpha fair value
Locked
Current Price
$9.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.